Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: A meta-analysis of individual patient data

C. Cammà, S. Bruno, F. Schepis, O. Lo Iacono, P. Andreone, A. G. Gramenzi, A. Mangia, A. Andriulli, M. Puoti, A. Spadaro, M. Freni, V. Di Marco, L. Cino, G. Saracco, A. Chiesa, A. Crosignani, N. Caporaso, F. Morisco, M. G. Rumi, A. Craxì

Research output: Contribution to journalArticlepeer-review

Abstract

Background and aims: Retreatment with a combination of α interferon (IFN) plus ribavirin of patients with chronic hepatitis C who did not respond to IFN monotherapy has not been assessed in large controlled studies. Methods: To assess the effectiveness and tolerability of IFN/ribavirin retreatment of non-responders to IFN and to identify predictors of complete (biochemical and virological) sustained response, we performed a meta-analysis of individual data on 581 patients from 10 centres. Retreatment with various IFN schedules (mean total dose 544 mega units) and a fixed ribavirin dose (1000-1200 mg/daily depending on body weight) was given for 24-60 (mean 39.5) weeks. Results: Biochemical end of treatment and sustained responses were observed in 271/581 (46.6%; 95% confidence interval (CI) 42.6-50.7%) and in 109/581 (18.7%; 95% CI 15.6-22.0%) cases, respectively. Two hundred and six of 532 patients (38.7%; 95% CI 34.6-42.9%) had an end of treatment complete response to retreatment while a complete sustained response occurred in 88 of 559 (15.7%; 95% CI 12.8-18.8%). Fifty four of 581 patients (9.2%; 95% CI 7.0-11.7%) stopped retreatment due to adverse effects. By logistic regression, complete sustained response was predicted independently by age

Original languageEnglish
Pages (from-to)864-869
Number of pages6
JournalGut
Volume51
Issue number6
DOIs
Publication statusPublished - Dec 2002

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: A meta-analysis of individual patient data'. Together they form a unique fingerprint.

Cite this